1015, 926 – 5 Avenue SW
Calgary, AB T2P 0N7
403 777 1519
Industry: Drug Manufacturers—Specialty & Generic
Full Time Employees:
|Mr. Ron Mayron||Exec. Chairman||288k||N/A||1963|
|Ms. Iris Bincovich||CEO & Director||645k||N/A||1969|
|Mr. Yoram Drucker||Founder, Exec. VP of Bus. Devel. & Director||398k||N/A||1965|
|Mr. Nelson Harvey Halpern F.C.A., FCPA||Chief Financial Officer||111k||N/A||1959|
|Mr. Nir Avram B.Sc., M.Sc.||Chief Technology Officer||N/A||N/A||N/A|
|Mr. Eyal Flom L.L.M., M.B.A.||Director & Company Sec.||N/A||N/A||1966|
|Roni Kamhi||Chief Operating Officer||N/A||N/A||N/A|
|Mr. Moshe Hukaylo||Chief Financial Officer of InnoCan Pharma Ltd.||N/A||N/A||N/A|
InnoCan Pharma Corporation, a pharmaceutical company, focuses on the development of various drug delivery platforms combining cannabidiol (CBD) with other pharmaceutical ingredients in the United States, Poland, France, and internationally. The company engages in the research and development of COVID-19 and other condition treatment by using CBD loaded exosomes; and CBD loaded liposomes. Its product includes CBD eye serum, CBD face oil, CBD face cream, CBD facial serum, CBD sleeping mask, CBD recovery lotion, and the Relief & Go spray. The company is also involved in the commercialization and sale of branded CBD integrated pharmaceutical and topical treatment products. InnoCan Pharma Corporation was incorporated in 2018 and is headquartered in Calgary, Canada.
InnoCan Pharma Corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.